Nasopharyngeal Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H1 2016', provides an overview of the Nasopharyngeal Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer - The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects - The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Nasopharyngeal Cancer Overview 10 Therapeutics Development 11 Pipeline Products for Nasopharyngeal Cancer - Overview 11 Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis 12 Nasopharyngeal Cancer - Therapeutics under Development by Companies 13 Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 15 Nasopharyngeal Cancer - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Nasopharyngeal Cancer - Products under Development by Companies 19 Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes 20 Nasopharyngeal Cancer - Companies Involved in Therapeutics Development 21 Ambrx, Inc. 21 Atara Biotherapeutics, Inc. 22 AVEO Pharmaceuticals, Inc. 23 Betta Pharmaceuticals Co. Ltd. 24 BioDiem Ltd 25 Biomics Biotechnologies Co., Ltd. 26 Celgene Corporation 27 Cell Medica Limited 28 F. Hoffmann-La Roche Ltd. 29 GlaxoSmithKline Plc 30 Merck & Co., Inc. 31 Molecular Partners AG 32 Ono Pharmaceutical Co., Ltd. 33 Pharmacyclics, Inc. 34 Sapvax 35 Shenzen SiBiono GeneTech Co., Ltd 36 Theravectys SA 37 Nasopharyngeal Cancer - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 abexinostat hydrochloride - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 azacitidine - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Cellular Immunotherapy for Multiple Sclerosis - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Cellular Immunotherapy for Oncology - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Cellular Immunotherapy for Oncology and Central Nervous System - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 CMD-003 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 DC-120 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 EBV-nRNA - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Epstein-Barr virus vaccine - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 ficlatuzumab - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 Gene Therapy to Activate p53 for Oncology - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 GSK-2849330 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 icotinib hydrochloride - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 MK-2206 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 MP-0250 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 MVA vaccine - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 NEO-212 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 nimotuzumab - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 nivolumab - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 RO-5203280 - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 SV-638 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 TT-10 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 Vaccine for Oncology - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Nasopharyngeal Cancer - Recent Pipeline Updates 101 Nasopharyngeal Cancer - Dormant Projects 125 Nasopharyngeal Cancer - Discontinued Products 126 Nasopharyngeal Cancer - Product Development Milestones 127 Featured News & Press Releases 127 Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 127 Appendix 128 Methodology 128 Coverage 128 Secondary Research 128 Primary Research 128 Expert Panel Validation 128 Contact Us 128 Disclaimer 129
List of Tables
Number of Products under Development for Nasopharyngeal Cancer, H1 2016 11 Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Investigation by Universities/Institutes, H1 2016 20 Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H1 2016 21 Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 22 Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 23 Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 24 Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H1 2016 25 Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 26 Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H1 2016 27 Nasopharyngeal Cancer - Pipeline by Cell Medica Limited, H1 2016 28 Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 29 Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 30 Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H1 2016 31 Nasopharyngeal Cancer - Pipeline by Molecular Partners AG, H1 2016 32 Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 33 Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 34 Nasopharyngeal Cancer - Pipeline by Sapvax, H1 2016 35 Nasopharyngeal Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H1 2016 36 Nasopharyngeal Cancer - Pipeline by Theravectys SA, H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Stage and Target, H1 2016 40 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Nasopharyngeal Cancer Therapeutics - Recent Pipeline Updates, H1 2016 101 Nasopharyngeal Cancer - Dormant Projects, H1 2016 125 Nasopharyngeal Cancer - Discontinued Products, H1 2016 126
List of Figures
Number of Products under Development for Nasopharyngeal Cancer, H1 2016 11 Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Products, H1 2016 18 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Top 10 Targets, H1 2016 39 Number of Products by Stage and Top 10 Targets, H1 2016 39 Number of Products by Top 10 Mechanism of Actions, H1 2016 41 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41 Number of Products by Routes of Administration, H1 2016 43 Number of Products by Stage and Routes of Administration, H1 2016 43 Number of Products by Molecule Types, H1 2016 45 Number of Products by Stage and Molecule Types, H1 2016 45
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposableRead More...
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growtRead More...
Global intelligent transportation system (ITS) market is estimated to attain USD 38.68 billion by 2020, as per a new research report by Radiant Insights, Inc. Cost effectiveness along with escalating need for road safety is likely to boost global demRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.